In the main study of nocturnal HOT in patients with CSA because of CHF (CHF-HOT), we reported significant improvements in oxygen desaturation index (ODI), apneahypopnea index (AHI), left ventricular ejection fraction (LVEF), and specific activity scale (SAS) following 12 weeks of nocturnal HOT in these patients. 18 The present study is designed to further evaluate the clinical efficacy and cost -benefit of nocturnal HOT, based on changes in the cost of illness following therapy, which is mainly consistent with the costs of hospitalization, emergency visits, and regular outpatient visits per year in patients undergoing nocturnal HOT for more than 6 months for the treatment of CSA associated with CHF.
Methods

Patients
Ambulatory patients aged over 20 years with clinical evidence of CHF were enrolled from 20 centers during June 2000 to April 2001, if they met the following criteria: (1) symptomatic with New York Heart Association (NYHA) Class II or III despite optimal medication for at least 2 weeks prior to study entry, (2) LVEF determined by radionuclide angiography or echocardiography ≤45%, (3) 4% ODI of ≥5 dips/h on pulse oximetry, and (4) at least 5 episodes of apnea and hypopnea per hour of sleep, of which more than 50% were central on screening polysomnographic examination. We strictly excluded subjects with predominantly obstructive sleep apnea, unstable angina, myocardial infarction within the previous 3 month, significant renal, neurological or respiratory diseases, or who were pregnant.
Analysis of Sleep Apnea
After written informed consent was given, the patients who met the inclusion criteria were monitored at home using a cardiorespiratory monitoring device (Someté, Compumedics, Australia) to analyze the proportion of central and obstructive sleep apnea during sleep. Available signals include ECG, nasal airflow, thoracic and abdominal effort, arterial O2 saturation (SpO2), pulse rate, and oximeter signal quality. Thoracoabdominal movements were recorded by respiratory inductance plethysmography, and the oxyhemoglobin saturation was monitored by a finger pulse oximetry. The system allows automatic respiratory event detection (central or obstructive sleep apnea, mixed apnea, hypopnea), SpO2 desaturation event recording and oximetry analysis. The ODI was the number of times per hour of sleep that the oxyhemoglobin saturation fell by ≥4%. The AHI was defined as the number of apnea and hypopnea episodes per hour of sleep. Apnea was defined as complete cessation of air flow for more than 10 s and hypopnea was defined as more than 70% attenuation of air flow accompanied with reduction of SpO2 ≥4%. Taken together, CSA was defined as apnea associated with a lack of thoracoabdominal movement.
Main Study
Following a baseline study, patients were randomly assigned to receive HOT at a rate of 3 L/min through nasal cannulas during sleep (nocturnal HOT group) or room air (Control group) for 12 weeks. O2 was delivered via a concentrator (TO-90-3N, Teijin Pharma Ltd, Tokyo, Japan). Patients assigned to the HOT group were instructed to use nasal O2 inhalation for at least 6 h during sleep.
Substudy: Follow-up Survey on Morbidity and Cost -Benefit Analysis
In the present study of CHF-HOT, a questionnaire survey was conducted to investigate the effects of HOT on morbidity in the study patients who continued HOT for more than 6 months, including the study periods, and further to add a cost -benefit analysis of HOT in clinical practice. The questionnaire survey was sent to 34 physicians at the 20 institutes who participated in the present CHF-HOT study. Patients from the control group who started nocturnal HOT after the study period were also included. The following issues were investigated: (1) frequencies (per year) and length of hospitalization because of worsening heart failure (HF), (2) frequency of emergency visits, and (3) regular outpatient visits immediately before and after using nocturnal HOT. Medical costs were estimated from the Diagnosis Procedure Combination (DPC)-MDC5 charge for hospitalization for worsening HF and the database of the Social Insurance Agency in the Ministry of Health and Welfare, February, 2003, Japan for universal application, and also from the standard model case estimation (Y.S. and H.I) for emergency visits and regular outpatient visits for CHF.
Cost -Benefit and Influence on Hospital-Care Days
In the present study, the cost -benefit analysis was based on changes in the cost of illness following nocturnal HOT, which was mainly consistent with costs of hospitalization, emergency visits, and regular outpatients visit per year. The reduction in the cost of illness following nocturnal HOT per year per patient was defined as the benefit from treatment. The charge for the use of nocturnal HOT per year per patient was defined as the cost. The time-saving benefit was assessed by analyzing the influence on the estimated days spent in hospital-care, which was estimated as the sum of (1) days of hospitalization; incidence of hospitalization (times/patient/year) multiplied by the mean days for hospitalization (day/once), (2) emergency visit days; incidence of emergency visits (time/patient/year), and (3) regular outpatient visits; incidence of visit (time/patient/year) multiplied by 0.25 (quarter day). The study protocol was approved by the Institutional Ethics Review Boards, and written informed consent was given by all patients prior to entry.
Results
Patients Characteristics
A total of 68 patients were enrolled from the 20 centers; 5 patients withdrew or were hospitalized before the start of nocturnal HOT, and 7 patients dropped out from the study during the 12-week study period. Thus, 56 patients (Table 1) were randomly assigned to receive either nocturnal O2 (HOT group, n=25) or room air (control group, n=31) for 12 weeks. From these 56 patients, those who continued HOT for more than 6 months including the study period, and patients from the control group who started nocturnal HOT after the study period, or other circumstances, were also included.
Follow-up Survey on Morbidity
The recovery rate of the questionnaire survey from treating physicians was 85.3%, and data regarding 53 patients were colleted. After using nocturnal HOT, the mean number of frequencies of hospitalization and of emergency visits was remarkably reduced from 2.1 to 0.5 times per year (76% reduction), and from 2.5 to 0.7 times per year (72% reduction), respectively. The length of hospitalization slightly reduced from 38.7 days to 34.6 days per hospitalization. Regular outpatient visits also reduced from 17.7 to 12.6 times per year (29% reduction) (Fig 1) .
Cost -Benefit Analysis
As shown in Table 2 , hospitalization costs, including inpatient medical expenses for 1 hospitalization because of worsening HF, were estimated as 1,634,970 yen/hospitalization on the basis of the charge for uncomplicated HF in DPC-MDC5 and the mean hospitalization days in the present subanalysis group (38.7 days); (50,160 yen/day × 11 days) plus (40,350 yen/day × 22 days) plus (34,300 yen/day × 5.7 days). To estimate the standard cost for hospitalization, we used the cost of uncomplicated HF in DPC-MDC5 and assumed the adjusting coefficient to be 1.0. Costs for an emergency visit consisted of outpatient medical fees (including overtime charge), outpatient examinations fees, labora- tory tests fees, and medication fees and were estimated as 8,880 yen/emergency visit; 1,300 yen, 3,750 yen, 3,470 yen, and 360 yen, respectively. Costs for a regular outpatient visit consisted of outpatient medical fee, basic and internal medicine dispensing fees, and medication dosage and guidance fee and were estimated as 1,240 yen/regular visit. Patients received standard medical treatment with diuretics (91% of the patients), ACE inhibitor (69% of the patients), -blockers (63% of the patients), and digitalis (55% of the patients) during the follow-up period. Thus the costs for drugs were estimated as 127,750 yen/year; 350 yen/day × 365 days for standard medical treatment prescribing diuretics (furosemide 80 mg/day, 37.8 yen/day), ACE inhibitor (enarapril 10 mg/day, 195.4 yen), -blocker (carvedilol 10 mg/day, 102 yen) and digitalis (digoxin 0.25 mg/day, 19.4 yen), and the costs for outpatient examination and tests were estimated as 29,380 yen/year. We assumed the following examinations were performed at regular intervals: chest X-ray 1.5 times/year (2,250 yen), 12-lead ECG 1.5 times/year (2,250 yen), echocardiography 1.5 times/year (12,000 yen), plasma brain natriuretic peptide concentration 4 times/year (5,800 yen), general blood cell counts 4 times/year (1,080 yen), and biochemical assay (6 items) 6,000 yen.
The cost -benefit analysis calculated a remarkable cost reduction following nocturnal HOT; namely, cost-reductions in hospitalization of 2,686,267 yen/patient/year: 3,433,437-747,170 yen, emergency visits of 15,984 yen/patient/year: 22,200-6,216 yen, and regular outpatient visits of 6,324 yen/patients/year: 179,078-172,754 yen, which would create an expected total cost reduction of 1,854,175 yen/year /patient, even after the added charge for HOT (854,400 yen/patient/year) (Fig 2) .
As the costs of hospitalization are a major component of the costs for the treatment of HF, we performed a sensitivity analysis according to the hospitalization period. The database of the Central Social Health Insurance Associations in the Ministry of Health and Welfare, 2003, reported the mean hospitalization period of uncomplicated HF for DPC MDC5 was 33 days. The sensitivity analysis revealed the cost-reduction would be expected for a hospitalization period exceeding 13 days.
Time-Saving Benefit
Furthermore, nocturnal HOT produced a remarkable decline in the estimated days spent in hospital-care (88.2 to 21.2 days/patient/year), thus the patient, and his or her family, gained an increase in the expected 67 days free from hospital-care following the induction of nocturnal HOT (Table 3, Fig 3) .
Discussion
Clinical Efficacy of Nocturnal HOT
The main study of CHF-HOT demonstrated that 12-week treatment with nocturnal HOT significantly increased the SAS, together with improvements in AHI and ODI, and a significant increase in LVEF in patients with CSA because of CHF. Thus the main study has shown that improvement in sleep quality associated with improved arterial deoxygenation and stabilization of sleep-disordered breathing increased daytime QOL and, furthermore, improved cardiac function in these patients. 18 The magnitude of the improvement in QOL assessed by the SAS in the present study was remarkable (1.0 Mets: 4.0±1.2 to 5.0±1.5 Mets vs 0.3 Mets: 4.4±0.2 to 4.7±0.2 Mets) compared with that observed in the previous trial of Effect of Pimobendan on Chronic Heart Failure (EPOCH) in Japan, which demonstrated the efficacy of the long-term treatment with the oral inotropic agent, pimobendan, on the QOL assessed by SAS in patients with similar severity of CHF. Furthermore the efficacy of nocturnal HOT on mortality and morbidity was prominent compared with the results of EPOCH, in which reduction in death and hospitalization because of worsening HF was 34% (10.1% in pimobendan group vs 15.3% patients with placebo) during a 52-week study period. 20 Recent large-scale randomized trials of -blockers in CHF also demonstrated significant reduction in hospitalization because of worsening HF. In th US-CHF trial, the carvedilol group showed 27% reduction in hospitalization compared with the placebo group. 21 In the CIBIS-II trial, the bisoprolol group showed 32% reduction in the hospitalization compared with placebo group. 22 The Multicenter carvedilol heart failure dose assessment study in Japan (MUCHA) showed that hospitalization rates because of worsening HF were significantly lower in the carvedilol high-dose group (2.6%, 88% reduction) and carvedilol low-dose group (2.1%, 91% reduction) than in the placebo group (20.4%). 23 The present CHF-HOT substudy demonstrated a remarkable reduction in the frequency of hospitalizations by 76%, from 2.1 to 0.5 times per year per patient following the introduction of HOT into the standard medical treatment of CHF. Suppression of worsening HF following nocturnal HOT was also evidenced in the remarkable reduction (72%) in emergency visits.
Cost -Benefit and Time-Saving Benefit of Nocturnal HOT
HOT represents a scientifically validated and universally accepted therapeutic regimen for the treatment of chronic hypoxemia secondary to chronic obstructive lung disease. In Japan, HOT has been already used by 124 million patients with chronic obstructive lung disease, and the benefit of HOT in these patients was reported to be in the shortening of hospitalization days (from 38 days to 16 days, 58%), which resulted in a marked cost -benefit. 24, 25 In the present study, the influence of HOT on the length of hospitalization was not so remarkable, thus if it could be shortened following nocturnal HOT the cost -benefit would be more increased.
Regarding another nocturnal breathing therapy for sleep apnea, beneficial effects of CPAP have been documented in patients with CHF and obstructive sleep apnea; that is, nocturnal CPAP markedly reduced obstructive sleep apnea, day time blood pressure and heart rate, and improved the LVEF. 4, 8 However the issue of long-term compliance with CPAP therapy has been frequently notedut. A recent report from Canada regarding the use of CPAP for the treatment of CSA in CHF could not necessarily document an improvement in long-term prognosis, mortality or heart transplantation, frequency of hospitalization, or QOL, even though beneficial effects were observed in nocturnal oxygen saturation, AHI, LVEF, or 6-min walk test following CPAP application. 26 In contrast, the CHF-HOT main study showed beneficial effects of the more convenient nocturnal HOT in patients with CSA because of CHF, 18 and the present study further demonstrated long-term beneficial effects on morbidity (frequency of hospitalization or emergency visits) and a cost -benefit following the introduction of nocturnal HOT. The cost -benefit analysis revealed a remarkable cost -benefit based on the reduction in frequencies of hospitalization (2.1 to 0.5 /year, 2,686,267 yen), emergency visits (2.5 to 0.7 /year, -15,984 yen), and regular outpatient visits (17.7 to 12.6 /year, -6,324 yen) following nocturnal HOT, which would create an expected cost-reduction of 1,854,175 yen/year/patient, even with the added charge for nocturnal HOT (854,400 yen/year). Similar analysis was reported in the study of intermittent milrinone therapy for patients with refractory HF (NYHA III-IV, LVEF <40%) at outpatient clinics in the United States. In that study, intermittent milrinone therapy for patients with intractable HF brought about 55% reduction in hospitalization, 72% reduction in hospitalization duration, and 52% reduction in emergency visits after beginning outpatient intermittent milrinone therapy, which should be a cost -benefit. 27 However, the benefit of milrinone therapy on the long-term prognosis has not been shown and may instead be deleterious in patients with ischemic etiology. 28 Another significant benefit in the present study was that nocturnal HOT produced a remarkable decline in the estimated days spent in hospital-care (88.2 to 22.1 days/patient/ year); namely, each patient gained 67 days/year free from hospital-care, which should be important for time-saving and QOL for the patients with moderate to severe CHF and also for their families.
Study Limitations
Whether the beneficial effects of nocturnal HOT continue persistently for a longer period is not yet clarified. In the present study, we analyzed the historical comparison between before vs after the introduction of HOT, and did not compare between patients on-HOT vs non-HOT groups. We used a simplified medical cost estimation, according to the DPC-MDC5 charge for universal application, to avoid overestimation of hospitalization cost. Furthermore, we assumed that medical treatment for HF was unchanged during the study period in terms of the standardized medication, which may change during the time course because of clinical improvement or worsening. Alternation in the adjusting coefficient, which was assumed to be 1.0 in the present analysis, would influence the estimation of costbenefit. Thus, further analyses on individual and timecourse related cost estimation should be clarified in the real world of therapy. The longer-term CHF-HOT II comparative study is on-going, and its results remain to be established.
